ADA2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09476(ADA2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09476(ADA2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The ADA2 antibody is associated with research on adenosine deaminase 2 (ADA2), a protein encoded by the *CECR1* gene. ADA2 functions as an extracellular enzyme involved in purine metabolism, converting adenosine to inosine and regulating extracellular adenosine levels. It plays roles in immune regulation, vascular development, and inflammation. Deficiencies in ADA2 due to genetic mutations cause *DADA2* (Deficiency of ADA2), a rare autosomal recessive disorder characterized by vasculopathy, immune dysregulation, and stroke.

ADA2 antibodies are not inherently pathological but have been studied as tools to detect or inhibit ADA2 activity in research contexts. In autoimmune diseases like VEXAS syndrome or certain vasculitides, autoantibodies targeting ADA2 have been reported, potentially disrupting its anti-inflammatory or vascular-protective functions. These antibodies may contribute to disease mechanisms by altering adenosine signaling or promoting endothelial dysfunction.

Commercial ADA2 antibodies are primarily used in immunoassays (ELISA, Western blot) or immunohistochemistry to quantify protein expression in studies exploring ADA2's role in immune disorders, angiogenesis, or hematopoiesis. Recent research also investigates ADA2 as a biomarker for disease severity in conditions like systemic lupus erythematosus or sepsis. However, the clinical relevance of endogenous ADA2 antibodies remains under investigation, with ongoing studies aiming to clarify their diagnostic or therapeutic potential.